chmcnfunds,
Great post,
“The dramatic reduction in the infectious viral load clearly establishes that we have extremely effective, direct-acting, antiviral drug candidates,” said Dr. Randall Barton, Chief Scientific Officer of the Company.
“Such a strong viral load reduction would enable even bird-flu infected patients to recover readily, assuming these results hold in humans,” said Eugene Seymour, MD, MPH, CEO of the Company.
This looks like someone could now become very interested in NNVC
FLUCIDE products and that we will still have to wait for the HUMAN TRIALS to get where we want to be as far as SP.
No mention of a second dose of FLUCIDE in the same test. Since there is no toxoicity what if a second or third dose is employed?
Good Results.
ECHCO20
Market Data 
Markets 
AI
